← All Biohaven LTD filings

Biohaven LTD DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NYSE
BHVN
Biohaven LTD
DEF: Biohaven Advances Key Programs, Faces FDA Setback
Biohaven Ltd. reports significant clinical progress in its immunology, epilepsy, and obesity programs, alongside a material adverse effect on stock value from an FDA approval failure.
NYSE
BHVN
Biohaven LTD
DEFA14A: Biohaven Ltd. Files Definitive Proxy Statement with SEC
Biohaven Ltd. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to its upcoming shareholder meeting.
NYSE
BHVN
Biohaven LTD
DEF: Biohaven Ltd. Awaits FDA Decision on Troriluzole for SCA, Advances Broad Pipeline
Biohaven Ltd. is preparing for a potential commercial launch of troriluzole for spinocerebellar ataxia (SCA) in Q3 2025, while also advancing its pipeline across multiple therapeutic areas.
NYSE
BHVN
Biohaven LTD
DEFA14A: Biohaven Ltd. Files Definitive Proxy Statement with SEC
Biohaven Ltd. has filed a definitive proxy statement with the Securities and Exchange Commission.
NYSE
BHVN
Biohaven LTD
DEF 14A: Biohaven Outlines Strategic Focus on Immunology, Neuroscience, and Oncology in Proxy Statement
Biohaven's proxy statement highlights the company's strategic shift towards immunology, neuroscience, and oncology, while also addressing challenges in the biopharma financial markets.